What anxiety treatment options are appropriate for a patient allergic to buspirone who is currently taking escitalopram 15 mg daily (and ropinirole) and has severe anxiety?

Optimize Current Escitalopram Dose First, Then Add CBT

For a patient already taking escitalopram 15 mg daily with severe anxiety (and a buspirone allergy), the most appropriate next step is to increase escitalopram to 20 mg daily and add cognitive behavioral therapy (CBT), as combination treatment demonstrates superior outcomes for anxiety disorders compared to medication alone. 1

Algorithmic Approach to Treatment

Step 1: Optimize Current SSRI Therapy

• Increase escitalopram from 15 mg to 20 mg daily after at least one week at current dose 2
• The FDA label for escitalopram indicates 10-20 mg/day is the therapeutic range for generalized anxiety disorder 2
• Escitalopram has the least effect on CYP450 enzymes compared to other SSRIs, making it ideal given concurrent ropinirole use (minimizes drug interactions) 1
• Allow 6-12 weeks at the optimized dose for full therapeutic effect, as maximal SSRI improvement typically occurs by week 12 1

Step 2: Add Cognitive Behavioral Therapy

• Combination CBT plus SSRI is superior to either treatment alone for anxiety disorders, with moderate strength of evidence 1
• The CAMS study demonstrated that combination treatment improved anxiety symptoms, global function, response rates, and remission rates compared to monotherapy 1
• CBT should be structured with approximately 14 sessions over 4 months, 60-90 minutes each 3

Step 3: If Inadequate Response After 12 Weeks

Consider these options in order:

1. Switch to another SSRI (sertraline, paroxetine, or fluvoxamine) 3

   • Sertraline is well-tolerated with less effect on drug metabolism 1
   • Avoid paroxetine if concerned about discontinuation syndrome 1

2. Switch to an SNRI (venlafaxine or duloxetine) 1

   • Venlafaxine demonstrated superiority over buspirone in GAD 4
   • Monitor blood pressure with venlafaxine 5

3. Add pregabalin as augmentation 6

   • Second-line option for GAD in adults
   • Requires renal dose adjustment

Critical Considerations

Why NOT Buspirone

• Patient has documented allergy to buspirone, making this contraindicated 7

Why NOT Benzodiazepines as First-Line

• Not recommended for routine use in anxiety disorders 8
• Risk of dependence, cognitive impairment, and falls
• Should be reserved for acute symptom management only

Why NOT Antipsychotics Initially

• Second-generation antipsychotics are second-line agents 6
• Higher side effect burden (weight gain, metabolic effects)
• Reserve for treatment-resistant cases

Drug Interaction Alert

• Escitalopram has minimal QT prolongation risk at doses ≤20 mg/day 1
• Avoid combining with other QT-prolonging drugs
• Monitor for serotonin syndrome if adding any serotonergic agents 1

Monitoring Strategy

• Assess response every 1-2 weeks during dose titration using standardized scales (HAM-A) 1
• Monitor for behavioral activation/agitation early in treatment, especially with dose increases 1
• Screen for suicidal ideation, particularly in first months and after dose adjustments 1
• Continue successful treatment for 6-12 months after remission before considering taper 8

Common Pitfalls to Avoid

1. Underdosing: Many patients remain on subtherapeutic doses; 20 mg escitalopram is often necessary 2
2. Premature switching: Allow adequate trial (12 weeks at therapeutic dose) before declaring treatment failure 1
3. Abrupt discontinuation: Taper gradually to avoid discontinuation syndrome 1, 2
4. Ignoring psychotherapy: Medication alone is less effective than combination treatment 1

The evidence strongly supports optimizing the current SSRI dose and adding CBT as the most effective, evidence-based approach for this patient with severe anxiety who cannot use buspirone. 1, 9